NCT06436144View on ClinicalTrials.gov

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

June 30, 2029

Study Completion Date

December 31, 2029

Conditions
Non Small Cell Lung CancerEGFR Gene MutationNon Small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IV
Interventions
DRUG

Osimertinib

Etoposide Soft Capsules Dosage：25mg/tablet, 2 tablets/time, taken continuously for 21 days, and stopped for one week. Osimertinib Dosage：80mg/tablet, 1 tablet/time, QD, taken for two cycles.

All Listed Sponsors
lead

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

OTHER

NCT06436144 - Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC | Biotech Hunter | Biotech Hunter